Company profile

Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

Privately held: no public share price (The company's own site places the Shaoxing entity inside Shanghai Leadingtac's structure; the group raised a RMB 100M Series A in 2024 and has not IPO'd. Parent: Shanghai Leadingtac Pharmaceutical Co., Ltd.. [resolved 2026-08-05 by resolve-null-is-public; source: https://en.leadingtac.com/news/companynews/496.html]) · China

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
LT-002-158
Phase 2
IRAK4Small molecule
Atopic Dermatitis
LT-010391
Phase 1
KRAS G12DSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.